Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1293 • ACR Convergence 2020
Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database
Rashmi Dhital¹, Joshua Baker², Paras Karmacharya³, Anthony Donato⁴ and Dilli Poudel², ¹Reading Hospital and Medical Center, West Reading, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester MN, ROCHESTER, MN, ⁴Reading Hospital and Medical Center, West Reading, PA
Background/Purpose: Early hospital readmission is a major healthcare burden. Studies evaluating factors associated with readmissions in rheumatic diseases are sparse. Our aim was to use…
Abstract Number: 1474 • ACR Convergence 2020
Early Peak of Cardiovascular Events Occurs Equally in Caucasians and African-American SLE but Is Attributed to Different Risk Factors
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: The classic bimodal pattern of morbidity/mortality in SLE highlighted that cardiovascular events occurred later in the natural history of SLE (Urowitz & Gladman. J…
Abstract Number: 1593 • ACR Convergence 2020
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus: Results of a Quality Improvement Initiative
Tara Skorupa¹ and Robert Shmerling², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center/Harvard Medical School, Division of Rheumatology, Mashpee, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. HCQ may rarely cause retinopathy.…
Abstract Number: 1678 • ACR Convergence 2020
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
Verena Balbi¹, Clovis Silva², Tatiana Pedrosa³, Rosa Pereira³, Lucia Campos³, Elaine Leon³, Nilo Duarte³, Valdemir Carvalho⁴, Sandra Pasoto³, Debora Rosario³, Leticia Brandao³, Eloisa Bonfa³ and Nadia Aikawa³, ¹Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao paulo, Brazil, ²Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Fleury Group, Sao Paulo, Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…
Abstract Number: 1790 • ACR Convergence 2020
Association of Telomere Length and the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) in Long Standing Systemic Lupus Erythematosus
Kaitlin Lima¹, Alexandra Legge², John Hanly², Jungwha Lee³, Jing Song³, Anh Chung³, Carly Skamra⁴, QiQuan Huang¹, Richard Pope⁵ and Rosalind Ramsey-Goldman⁶, ¹Northwestern University, Chicago, IL, ²Dalhousie University, Halifax, NS, Canada, ³Northwestern University, Chicago, ⁴Northwestern University, Brookfield, IL, ⁵McGaw Medical Center of Northwestern University, Chicago, IL, ⁶Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Frailty, an emerging concept in SLE, represents an individual’s ability to respond to physiologic stress. The first lupus-specific frailty index, the SLICC-FI, was recently…
Abstract Number: 1808 • ACR Convergence 2020
Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
Jill Buyon¹, John Conklin², Michael Golpanian¹, JoAnne Ligayon³, Thierry Dervieux⁴, Peter Izmirly¹, H. Michael Belmont¹, Jane Salmon⁵ and Roberta Vezza Alexander³, ¹New York University, New York, NY, ²Exagen Inc., Vista, CA, ³Exagen Inc, Vista, CA, ⁴Exagen Inc, San Diego, CA, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Despite improvement in management and outcomes of pregnancies complicated by SLE, the risk of adverse events and preeclampsia (PE) continues to exceed that of…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: 1842 • ACR Convergence 2020
Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial
Anca Askanase¹, George Wan², Mary Panaccio², Enxu Zhao², Julie Zhu², Roman Bilyk² and Richard Furie³, ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment…
Abstract Number: 0246 • ACR Convergence 2020
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
Rory Monahan¹, Rolf Fronczek¹, Jeroen Eikenboom¹, Huub Middelkoop¹, Liesbeth Beaart-van de Voorde¹, Gisela Terwindt¹, Nic van der Wee¹, Thomas Huizinga¹, Margreet Kloppenburg¹ and Margreet Steup-Beekman¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Fatigue is commonly described in chronic illnesses, especially in auto-immune disorders such as systemic lupus erythematosus (SLE). We aim to study the prevalence of…
Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 0279 • ACR Convergence 2020
Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus
Naci Senkal¹, Esen Kiyan², Elif Kocasoy-Orhan³, Ali Demir⁴, Mehmet Aydogan⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Murat Inanc⁷, Mahdume Lale Öcal⁶ and Bahar Artım-Esen⁶, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ²Department of Chest Disease, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ³Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁴Fulya Radiologic Imaging Center, İstanbul, Turkey, ⁵Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁶Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁷Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: The prevalence of SLE pulmonary involvement varies depending on several factors, including diagnostic methods. In this study, we sought to determine the frequency of…
Abstract Number: 0297 • ACR Convergence 2020
Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon
Melissa Northcott¹, Linden Gearing², Hieu Nim³, Champa Nataraja³, Sarah Jones¹ and Eric Morand⁴, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ²Hudson Institute of Medical Research, Clayton, Victoria, Australia, ³Monash University, Clayton, Victoria, Australia, ⁴Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC), utilised in SLE for their broad immunosuppressive actions, predominantly mediate these effects by interaction with the cytoplasmic GC receptor (GR) to modulate…
Abstract Number: 0462 • ACR Convergence 2020
Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome
Brian Dizon¹, Rishi Goel², Shuichiro Nakabo², Amanda Urban², Meryl Waldman², Lilian Howard², Dirk Darnell², Munir Buhaya², Sarfaraz Hasni³, Mariana Kaplan⁴, Alexandra Freeman² and Sarthak Gupta¹, ¹National Institutes of Health, BETHESDA, MD, ²National Institutes of Health, Bethesda, ³Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Autosomal dominant hyper-IgE syndrome (AD-HIES), also known as Job’s syndrome, is a rare primary immunodeficiency caused by dominant-negative loss-of-function (LOF) mutations in signal transducer…
Abstract Number: 0591 • ACR Convergence 2020
Intervention to Improve SLE Medication Adherence Using Surescripts Pharmacy Refill Data
Kai Sun¹, Jennifer Rogers², Rebecca Sadun³, Amanda Eudy³, Jayanth Doss³, Lisa Criscione-Schreiber⁴, Ann Cameron Barr⁵, Lena Eder⁶, Mithu Maheswaranathan³, Amy Corneli⁷, Hayden Bosworth¹ and Megan Clowse⁸, ¹Duke University Hospital, Durham, ²Duke University Hospital, Durham, DE, ³Duke University, Durham, NC, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, Duke University Medical Center, Durham, NC, ⁵Duke University Hospital, Durham, NC, ⁶Duke University Hospital, Chapel Hill, NC, ⁷Duke University, Durham, ⁸Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 80% among SLE patients and leads to higher morbidity, mortality, and healthcare costs. Few studies have tested interventions…
Abstract Number: 0846 • ACR Convergence 2020
MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
Ram Singh¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: B cell depletion or modulation is emerging as a major treatment modality for autoimmune diseases. However, the current treatments to accomplish this non-specifically target…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].